Ipnovel (Midazolam)

Midazolam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the inhibitory action of GABA. This increases chloride influx, hyperpolarising neurons and reducing excitability, which produces sedation, anxiolysis, anticonvulsant and hypnotic effects.

The dose of Ipnovel is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition and the intended level of sedation. Specific dosing regimens are determined at the point of care.

Midazolam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is generally avoided during pregnancy unless the benefit outweighs the risk, and it is not recommended for breastfeeding mothers because it can pass into breast milk.

To order Ipnovel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipnovel (midazolam) is a short‑acting benzodiazepine, offering faster onset and shorter recovery than longer‑acting agents such as diazepam or lorazepam. This makes it preferable for brief procedures and rapid seizure control, while alternative agents may be chosen for longer sedation needs.

Ipnovel should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. The solution must be kept in a clean, dry environment and inspected for particulate matter before use.

Ipnovel is supplied as an intravenous solution and is administered directly into a vein by a qualified healthcare professional. It can be given as a bolus injection or continuous infusion, depending on the clinical situation and desired depth of sedation.

The most serious risks include severe respiratory depression, profound hypotension, paradoxical reactions such as agitation, anaphylaxis, and cardiac arrhythmias. Continuous monitoring of respiratory and cardiovascular status is essential during and after administration.

Ipnovel is contraindicated in patients with known hypersensitivity to midazolam or other benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals with myasthenia gravis where muscle weakness may be exacerbated.